505(b)(2) Resurrection, FDA Guidance To Bless Follow-On Biologics Pathway

FDA's decision to develop guidance for development of follow-on versions of biologics approved under the Food, Drug & Cosmetic Act indicates the agency has accepted section 505(b)(2) of the FD&C Act as a viable pathway for approval of such products